Australians living with inoperable malignant mesothelioma will soon have access to an immunotherapy listed on the Pharmaceutical Benefits Scheme. [ + ]

One of the grant recipients will investigate the medium- and long-term impacts of COVID-19 on patients' health and wellbeing. [ + ]

The Global Cardiovascular Research Funders Forum aims to to advance the prevention, diagnosis and treatment of cardiovascular conditions such as heart attack and stroke. [ + ]

RMIT researchers have developed smart wound dressings with built-in nanosensors that glow to alert patients when a wound is not healing properly. [ + ]

Navbit Sprint is an innovative device that helps surgeons place and align the acetabular cup, a component that is inserted into the hip socket during joint replacement surgery. [ + ]

Roche Australia has joined ANDHealth's cooperative digital health commercialisation initiative to support the development and growth of Australia's digital health ecosystem. [ + ]

A new health and wellbeing age calculator has revealed that some age groups have an average health age of up to nine years older than their chronological age. [ + ]

Flinders University has become a research partner of the Freemasons Centre for Male Health & Wellbeing, broadening the scope and footprint of the centre's activities. [ + ]

Australian scientists have discovered that regular fish oil has the potential to break down superbugs' ability to become resistant to antibiotics. [ + ]

PanKind has launched the PanKind Early Detection Initiative in a move to strategically work with the research community to improve early diagnosis of pancreatic cancer. [ + ]

Monash University and BiVACOR are leading a consortium of universities, hospitals and industry to develop and commercialise the world's first durable total artificial heart. [ + ]

World Allergy Week is seeking to raise awareness of allergies and anaphylaxis, with leading allergy organisations promoting important resources that could save lives. [ + ]

Novavax's COVID-19 vaccine demonstrated 100% protection against moderate and severe disease, with 90.4% efficacy overall, in the PREVENT-19 Phase 3 trial. [ + ]

The partnership should ensure Australia's hospitals, aged-care and healthcare providers are efficiently equipped to deliver best-in-class care to patients. [ + ]

Solaris Paper's ANZ companies are looking to strategically move ahead of the curve in new production innovation. [ + ]